SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-07-2110. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-07-2110v1 101/5/2067    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vij, R. Articles by Adkins, D. Search for Related Content PubMed PubMed Citation Articles by Vij, R. Articles by Adkins, D. Related Collections Transplantation Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2003, Vol. 101, No. 5, pp. 2067-2069 TRANSPLANTATION Brief report Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation Ravi Vij, John F. DiPersio, Partha Venkatraman, Kathryn Trinkaus, Lawrence T. Goodnough, Randy A. Brown, Hanna J. Khoury, Steven M. Devine, Aarti Oza, Shalini Shenoy, William Blum, and Douglas Adkins From the Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis; and Division of Pediatric Hematology Oncology, Washington University School of Medicine, St Louis, MO. We studied the impact of donor cytomegalovirus (CMV) serologic status on CMV viremia and disease when prophylactic granulocyte colony-stimulating factor (G-CSF)-mobilized granulocyte transfusions (GTs) were given following allogeneic peripheral blood stem cell (AlloPBSC) transplantation. A cohort of 83 patients who received 2 prophylactic GTs from ABO-compatible stem cell donors following AlloPBSC transplantation was compared with a cohort of 142 patients who did not. AlloPBSC donors were eligible for granulocyte donation irrespective of their CMV serostatus. Recipients received no prophylactic therapy for CMV. Donor CMV serostatus had no impact on CMV viremia and disease in the 2 cohorts. Our data show that in an era of effective surveillance and preemptive therapy for CMV, AlloPBSC recipients can safely receive 2 transfusions of prophylactic G-CSF-mobilized granulocyte components from CMV-seropositive AlloPBSC donors. This knowledge may help expand the donor pool in areas with a high prevalence of CMV in the general population. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. G. Nichols, T. Price, M. Boeckh, R. Vij, J. DiPersio, H. Khoury, L. T. Goodnough, S. M. Devine, W. Blum, and D. Adkins Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions Blood, June 15, 2003; 101(12): 5091 - 5092. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020